AstraZeneca Announces $35 Monthly Cap on Inhaler Prices in Response to Healthcare Affordability Concerns
In a significant move for asthma and COPD patients, AstraZeneca will cap the cost of its inhalers at $35 per month starting from June 2024. This decision, mirroring a rival's earlier action, aims to improve affordability amidst legislative scrutiny and allegations of anti-competitive practices.
Continue reading...